Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 3
2011 3
2012 1
2013 1
2014 2
2015 2
2016 2
2017 4
2018 1
2019 1
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, Du C, Chen Y, Chen X, Yang L, Chen W, Wong RW, Wai LE, Wang T, Zhang Q, Chen W. Yang F, et al. Among authors: koh s. Hepatol Int. 2023 Aug;17(4):850-859. doi: 10.1007/s12072-023-10524-x. Epub 2023 Apr 17. Hepatol Int. 2023. PMID: 37067675 Clinical Trial.
Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, Shi M, Li Y, Xie Y, Liu LM, Zhou CB, Chua A, Ho ZZ, Luan J, Zhao J, Li J, Wai LE, Koh S, Wang T, Bertoletti A, Wang FS. Tan AT, et al. Among authors: koh s. Hepatol Commun. 2022 Apr;6(4):841-854. doi: 10.1002/hep4.1857. Epub 2021 Dec 21. Hepatol Commun. 2022. PMID: 34935312 Free PMC article.
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS. Meng F, et al. Among authors: koh s. Hepatol Int. 2021 Dec;15(6):1402-1412. doi: 10.1007/s12072-021-10250-2. Epub 2021 Nov 30. Hepatol Int. 2021. PMID: 34850325 Free PMC article. Clinical Trial.
Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Tan AT, et al. Among authors: koh s. Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31. Gastroenterology. 2019. PMID: 30711630 Free article.
T-cell therapy for chronic viral hepatitis.
Bertoletti A, Tan AT, Koh S. Bertoletti A, et al. Among authors: koh s. Cytotherapy. 2017 Nov;19(11):1317-1324. doi: 10.1016/j.jcyt.2017.07.011. Epub 2017 Aug 25. Cytotherapy. 2017. PMID: 28847469 Review.
24 results